严重急性呼吸系统综合征冠状病毒2(SARS-CoV-2)与严重急性呼吸系统综合征冠状病毒(SARS-CoV)一样,是通过S-蛋白与人细胞表面血管紧张素转化酶2(ACE2)受体的介导作用进行入侵,感染人的呼吸道上皮细胞或角膜和结膜组织而进入体内。目前研究表明,高表达ACE2蛋白的器官如肾脏、肺部更易受到病毒侵害,围绕SARS-CoV-2与ACE2结合过程的相关药物研发也在不断的推进。本文通过综述已发表的与ACE2和SARS-CoV-2感染相关的文献资料,以ACE2为讨论对象,重点阐述其体内分布以及与SARS-CoV-2感染患者器官损伤等方面的相关性,同时系统综述目前作用于SARS-CoV-2与ACE2结合过程的药物研发进展,以期为临床抗击SARS-CoV-2感染提供参考。
Abstract
SARS-CoV-2, which is similar to SARS-CoV, can bind to human cell surface receptor ACE2 through its S-protein, sequentially infecting human cells such as respiratory epithelial cells or corneal and conjunctival tissues, thereby invading the human body. Recent studies have shown that organs with high expression levels of ACE2 protein, such as kidneys and lungs, are more vulnerable to virus damage. Therefore, lots of efforts have been devoted to the development of drugs targeting the combination of SARS-CoV-2 and ACE2. This paper reviewed the most recently published literatures that related to ACE2 and coronavirus infection, with an emphasis on ACE2, especially its distribution in vivo and organ damages of the patients with SARS-CoV-2 infection, as well as recent progress of drug development targeting the binding process of SARS-CoV-2 and ACE2. This paper aimed to shed some light on clinically fight against SARS-CoV-2 infection.
关键词
新型冠状病毒肺炎 /
血管紧张素转换酶2 /
器官损伤 /
药物研发
{{custom_keyword}} /
Key words
COVID-19 /
ACE2 /
organ injury /
drug development
{{custom_keyword}} /
中图分类号：
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] HOFFMANN M. The novel coronavirus 2019 (2019-NcOv) uses the ARS coronavirus receptor ACE2 and the cellular for entry into protease TMPRSS2 target cells[DB/OL]. BioRxiv. [2020-03-11]. https://doi.org/10.1101/2020.01.31.929042.
[2] TIAN X L, LI C, HUANG A L, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody[J]. Emerg Microbes Infect, 2020,9(1):382-385.
[3] WRAPP D, WANG N S, CORBETT K S, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020, 367(6483):1260-1263.
[4] XU X T. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J]. Sci China Life Sci, 2020, 63(3):457-460.
[5] LI X, DUAN G Y, ZHANG W, et al. A furin cleavage site was discovered in the S protein of the 2019 novel coronavirus[J]. Chin J Bioinform(生物信息学),2020,18(2):1-4.
[6] CAI G S. Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov [DB/OL]. BioRxiv. [2020-03-11]. https://www.preprints.org/manuscript/202002.0051/v3.
[7] ZHAO Y. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov [DB/OL]. BioRxiv. [2020-03-11]. https://doi.org/10.1101/2020.02.11.20022228.
[8] ZHANG Y, TANG D Z, SHU B, et al. Evaluation and analysis on the SARS-CoV-2-induced injuries in multiple organs and the intervention of traditional Chinese medicine based on renin-angiotensin system[J]. World Sci Technol Mod Tradit Chin Med(世界科学技术—中医药现代化),2020,22(2):1-7.
[9] WU Y T. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury[DB/OL]. Virol Sin.[2020-02-07]. https://link.springer.com/article/10.1007/s12250-020-00205-6.
[10] HUANG C L, WANG Y M, LI X W, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10233):497-506.
[11] HAMMING I, TIMENS W, BULTHUIS M L C, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis[J]. J Pathol, 2004, 203(2):631-637.
[12] ZOU X, CHEN K, ZOU J W, et al. The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to Wuhan 2019-nCoV infection[DB/OL]. Front Med. [2020-03-12]. https://link.springer.com/article/10.1007%2Fs11684-020-0754-0.
[13] LI Z. Caution on Kidney Dysfunctions of 2019-nCoV Patients [DB/OL]. BioRxiv. [2020-03-11]. https://doi.org/10.1101/2020.02.08.20021212.
[14] ZHANG H. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes [DB/OL]. BioRxiv. [2020-03-11]. https://doi.org/10.1101/2020.01.30.927806.
[15] JIA H P. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease[J]. Shock, 2016, 46(3):239-248.
[16] IMAI Y, KUBA K, RAO S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure[J]. Nature, 2005, 436(7047):112-116.
[17] ZHANG M, LI C, Novel coronavirus pneumonia and cardiovascular disease[J]. Med J Chin PAPF(武警医学),2020, 2(31):93-96.
[18] LIU Y X, YANG Y, ZHANG C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury[J]. Sci China Life Sci, 2020, 63(3):364-374.
[19] LI G D, CLERCQ E D. Therapeutic options for the 2019 novel coronavirus (2019-nCoV)[J]. Nat Rev Drug Discov, 2020, 19(3):149-150.
[20] FAN C B. ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection [DB/OL]. MedRxiv. [2020-03-11]. https://doi.org/10.1101/2020.02.12.20022418.
[21] CHAI X Q. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection [DB/OL]. BioRxiv. [2020-03-11]. https://doi.org/10.1101/2020.02.03.931766.
[22] MORSE J S, LALONDE T, XU S Q, et al. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV[J]. Chem Bio Chem, 2020, 21(5):730-738.
[23] LIU Q Y, WANG X L. Strategies for the development of drugs targeting novel coronavirus 2019-nCoV[J]. Acta Pharm Sin(药学学报),2020,55(2):181-188.
[24] KUBA K, IMAI Y, RAO S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury[J]. Nat Med, 2005, 11(8):875-879.
[25] LI H, TAN X C, JIANG D, et al. Research progress on coronavirus and its therapeutic drugs[J]. Chin Pharm J(中国药学杂志),2020, 55(4):284-292.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金青年基金项目资助(81903849);浙江省卫生健康委员会创新人才支持计划项目资助(2020RC009);浙江省中医药科技计划项目青年人才基金资助(2018ZQ033);“十三五”浙江省中医药(中西医结合)重点学科建设计划项目资助(2017-xk-A35)
{{custom_fund}}
PDF(4528 KB)
